IGF-1 and growth response to adult height in a randomized GH treatment trial in short non-GH-deficient children

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

The objective of the study was to analyze the relationship between IGF-1SDS, IGF binding protein-3 SDS (IGFBP3SDS), and their ratioSDS with a gain in the heightSDS until AH in non-GH-deficient short children.

Who Took Part

The study group was 112 children.

By PubMed's age tags, the people studied were children, teenagers and adults, both men and women.

One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS).

How the Study Was Run

In design terms this was a randomized and multicenter study.

The children were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

Running at several centres spread the IGF-1 LR3 study over different clinics and patient groups.

This was a randomized, controlled, multicenter clinical trial.

What Was Measured

The subject headings attached to it are Body Height, Child Development, Dwarfism, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3 and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized and multicenter study of IGF-1 LR3 in 112 children.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.